Regelink JC, Raijmakers PG, Bravenboer N, Milek R, Hoetjes NJ, de Kreuk AM, van Duin M, Wondergem MJ, Lips P, Sonneveld P, Zijlstra JM, Zweegman S. (18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma.
EJNMMI Res 2016;
6:46. [PMID:
27246327 PMCID:
PMC4887457 DOI:
10.1186/s13550-016-0197-4]
[Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2016] [Accepted: 05/16/2016] [Indexed: 11/30/2022] Open
Abstract
Background
Bone disease in multiple myeloma is characterized by reduced bone formation. The gold standard of bone formation is the mineral apposition rate (MAR), an invasive technique reflecting bone formation at a single site. We compared 18F-fluoride-PET with the MAR in myeloma patients.
Methods
Bone formation was measured before and after bortezomib treatment by determination of the MAR in iliac bone marrow biopsies and the measurement of 18F-uptake.
Results
The inter- and intra-individual variations in 18F-uptake (SUVA50%) were pronounced as 33.50 (range 4.42 to 37.92) and 27.18 (range 4.00 to 31.18), respectively. A significant correlation between the MAR and 18F-uptake was found (r = 0.80, p = 0.017). There was a heterogeneous response after treatment varying from −2.20 to 4.53.
Conclusions
Iliac 18F-uptake was associated with the local MAR in myeloma patients. Furthermore, 18F-fluoride-PET demonstrated the heterogeneity of in vivo bone formation, enabling monitoring during treatment.
Electronic supplementary material
The online version of this article (doi:10.1186/s13550-016-0197-4) contains supplementary material, which is available to authorized users.
Collapse